Aldeyra Therapeutics, Inc. ALDX
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $25.7M | $48.2M | $29.5M | $47.3M | $44.9M | $24.7M | $44.4M | $29.8M | $16.3M | $13.2M |
| SG&A | $9.6M | $11.9M | $13.3M | $15.4M | $11.3M | $10.0M | $12.2M | $9.9M | $6.2M | $5.5M |
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M | -$56.2M | -$36.4M | -$63.1M | -$39.7M | -$22.5M | -$18.7M |
| Interest expense | $1.9M | $1.9M | $2.1M | $1.7M | $1.7M | $1.9M | $603.8K | $146.8K | $113.5K | $105.5K |
| Pre-tax income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | -$57.8M | -$38.0M | -$62.1M | -$38.9M | -$22.3M | -$18.7M |
| Income tax | $0 | $1.0K | $0 | $0 | $0 | $479.3K | $1.3M | $0 | $0 | $0 |
| Net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | -$57.8M | -$37.6M | -$60.8M | -$38.9M | -$22.3M | -$18.7M |
| EPS, basic | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 | — | — | — | — | — |
| EPS, diluted | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 |
| Shares, diluted (wtd. avg.) | 60.1M | 59.5M | 58.9M | 58.4M | 54.0M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $70.0M | $54.5M | $142.8M | $144.4M | $229.8M | $77.9M | $44.4M | $47.4M | $20.0M | $12.0M |
| Short-term investments | $0 | $46.6M | $0 | $29.9M | $0 | $0 | $28.9M | $46.2M | — | — |
| Total current assets | $71.8M | $104.1M | $147.8M | $181.0M | $232.8M | $83.1M | $75.2M | $94.8M | $44.0M | $25.1M |
| Property, plant and equipment | — | $0 | $5.8K | $19.3K | $32.5K | $59.9K | $148.4K | $235.2K | $43.3K | $56.4K |
| Total assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M | $83.4M | $75.5M | $95.1M | $44.2M | $25.2M |
| Accounts payable | $158.5K | $180.5K | $1.3M | $133.6K | $1.0M | $381.6K | $808.3K | $3.1M | $1.0M | $275.4K |
| Short-term debt | $15.2M | $31.4K | $15.1M | $911.8K | — | — | — | — | $116.3K | $77.5K |
| Total current liabilities | $27.8M | $18.6M | $22.3M | $15.4M | $11.8M | $12.4M | $12.9M | $8.5M | $3.4M | $2.3M |
| Long-term debt | $0 | $15.0M | $0 | $14.9M | $15.5M | $11.4M | $14.5M | — | $1.2M | $1.2M |
| Total liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M | $23.8M | $27.4M | $8.5M | $4.6M | $3.5M |
| Retained earnings | -$484.0M | -$450.1M | -$394.3M | -$356.7M | -$294.7M | -$236.9M | -$199.4M | -$138.5M | -$99.6M | -$77.3M |
| Total equity | $44.3M | $71.0M | $119.8M | $151.0M | $205.7M | $59.5M | $48.1M | $86.6M | $39.6M | $21.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.6M | -$42.6M | -$37.5M | -$45.0M | -$29.9M | -$19.2M | -$15.1M |
| Depreciation and amortisation | $252.0K | $249.6K | $262.8K | $258.7K | $264.2K | $56.2K | $96.3K | $71.0K | $37.8K | $35.8K |
| Stock-based compensation | $6.1M | $8.0M | $5.8M | $8.3M | $7.1M | $7.1M | $8.1M | $4.1M | $2.7M | $2.8M |
| Capital expenditure | — | — | $0 | $16.3K | $7.8K | — | $9.5K | $263.0K | $24.8K | $11.8K |
| Investing cash flow | $47.7M | -$44.9M | $30.0M | -$30.0M | -$7.8K | $29.0M | $18.5M | -$23.3M | -$10.2M | -$225.2K |
| Financing cash flow | $1.1M | -$171.4K | -$1.3M | $1.2M | $194.5M | $41.9M | $23.6M | $80.5M | $37.4M | $12.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182099.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$18.7M | -$22.3M | -$38.9M | -$60.8M | -$37.6M | -$57.8M | -$62.0M | -$37.5M | -$55.9M | -$33.8M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Officer or director change Item 5.02
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |